Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2000;96:366-372
© 2000 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SYMONS, J.
Right arrow Articles by SPEROFF, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SYMONS, J.
Right arrow Articles by SPEROFF, L.

ORIGINAL RESEARCH

Vaginal Bleeding in Postmenopausal Women Taking Low-Dose Norethindrone Acetate and Ethinyl Estradiol Combinations

JAMES SYMONS, PhD, NONA KEMPFERT and LEON SPEROFF, MD FOR THE FemHRT STUDY INVESTIGATORS

From the Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan; and the Oregon Health Sciences University, Portland, Oregon.

Address reprint requests to: James Symons, PhD Parke-Davis Pharmaceutical Research 2800 Plymouth Road Ann Arbor, MI 48105 E-mail: james.symons{at}wl.com

Objective: To determine the effect of continuous combined treatment with norethindrone acetate and ethinyl estradiol (E2) on vaginal bleeding, spotting, or bleeding and/or spotting in postmenopausal women.

Methods: Two randomized clinical trials were conducted in which participants recorded information on the daily occurrence of vaginal bleeding or spotting. In study 1, 219 postmenopausal women reporting at least ten hot flushes per week were randomized to placebo or one of four treatment groups (0.2 mg norethindrone acetate/1 µg ethinyl E2, 0.5 mg norethindrone acetate/2.5 µg ethinyl E2, 1 mg norethindrone acetate/5 µg ethinyl E2, or 1 mg norethindrone acetate/10 µg ethinyl E2). In study 2, 266 postmenopausal women reporting at least 56 moderate to severe hot flushes were randomized to placebo or one of three treatment groups (0.5 mg norethindrone acetate/2.5 µg ethinyl E2, 1 mg norethindrone acetate/5 µg ethinyl E2, or 1 mg norethindrone acetate/10 µg ethinyl E2). The total duration of treatment was 16 weeks in study 1 and 12 weeks in study 2. In both studies, subjects reported in daily diaries whether they had either bleeding or spotting.

Results: In study 1, there was a significantly greater relative risk (RR) for bleeding in the group receiving 1 mg norethindrone acetate/10 µg ethinyl E2 at study weeks 4 and 8 (RR = 1.36 and 95% confidence interval [CI] 1.01, 1.83; RR = 1.37 and 95% CI 1.1, 1.72; respectively) compared with placebo, but not at study weeks 12 or 16. The group receiving 1 mg norethindrone acetate/5 µg ethinyl E2 also had a significantly greater risk at weeks 4 and 8 (RR = 1.5 and 95% CI 1.15, 1.96; RR = 1.33 and 95% CI 1.00, 1.77; respectively), whereas the other dose combinations did not differ from placebo. Results from study 2 were similar to those of study 1.

Conclusion: Although there was a greater risk for bleeding and/or spotting at the higher doses of norethindrone acetate and ethinyl E2, this risk declined over time. If compliance with hormone replacement therapy regimens is influenced at least in part by vaginal bleeding, the combined norethindrone acetate/ethinyl E2 regimen investigated in these studies may provide a treatment option.




This article has been cited by other articles:


Home page
 Evid. Based Nurs.Home page
Other Articles Noted
Evid. Based Nurs., October 1, 2001; 4(4): E1 - 11.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Obstetricians and Gynecologists.